

## Cirrhosis for the Hospitalist

Anna Rutherford, MD, MPH  
Clinical Director of Hepatology  
BWH Clinical Director of MGB Liver Transplant  
Brigham & Women's Hospital  
Assistant Professor of Medicine  
Harvard Medical School



Anna Rutherford, MD, MPH

- M.D., Harvard Medical School
- M.P.H, Harvard School of Public Health
- GI Fellowship & Advanced Hepatology Fellowship, Massachusetts General Hospital
- Assistant Professor of Medicine, Harvard Medical School
- Transplant Hepatologist, Mass General Brigham Liver Transplant Program
- Clinical Director of Hepatology, Brigham & Women's Hospital

I have no disclosures relevant to this presentation.



## Learning Objectives

- Natural history and outcome of cirrhosis
- Initial management of complications of cirrhosis
- Updates/Recent studies on management of complications of cirrhosis
- Appropriate timing of referral for liver transplantation
- Pre-operative risk assessment in patients with cirrhosis

## Patient RS

52 year old with alcohol and HCV cirrhosis  
Sober for 5 years


Recently developed ascites → now on Furosemide,  
Spironolactone, low salt diet

Family thinks he is unsafe to drive due to inattention →  
Lactulose recently started


Comes in to ER with diffuse abdominal pain and distension  
and confusion

While he is being evaluated in ER, his wife asks you how  
long he can live like this?

## Natural History of Chronic Liver Disease



## Probability of Hepatic Decompensation: 58% over 10 years




Hepatology 1987; 7: 122-128

## Risk Factors for Hepatic Decompensation


- GI Bleeding
- Infection
- Alcohol intake
- Medications
- Dehydration
- Constipation
- Obesity (Hepatology 2011; 54: 555)
- Surgery
- Ongoing viral infection

## Hepatic Decompensation Reduces Survival



Hepatology 1987; 7: 122-128

## Prediction of 3-Month Survival in Patients with Cirrhosis




MELD score =  $3.8 \ln(\text{bilirubin}) + 11.2 \ln(\text{INR}) + 9.6 \ln(\text{creatinine}) + 6$

## Prediction of 1 Year Survival in Patients with Cirrhosis: Child Turcotte Pugh Score

Points	1	2	3
Encephalopathy	None	1 and 2	3 and 4
Ascites	Absent	Slight	Moderate
Bilirubin (mg/dL)	1-2	2-3	>3
Albumin (g/dL)	3.5	2.8-3.5	<2.8
INR	<1.7	1.7-2.3	>2.3

5-6    A    100% 1 year survival  
7-9    B    80% 1 year survival  
10-15    C    45% 1 year survival

## Natural History of Ascites from Cirrhosis



## Management of Ascites

- 50% of patients with compensated cirrhosis will develop ascites 10 years from diagnosis
- Development of ascites associated with reduction in 5-year survival from 80% to 30%
- Ascites most common complication of cirrhosis that leads to hospital admission
- New-onset ascites requires diagnostic paracentesis
- Bleeding complications in less 1/1,000 who require paracentesis
- Use of blood products (FFP/platelets) for paracentesis not data supported
- SAAG of  $\geq 1.1$  is 97% accurate for portal hypertension
- High ascitic total protein ( $>2.5\text{g/dL}$ ) suggests cardiac ascites

AASLD Practice Guidance : Hepatology 2021; 74: 1014–1048.

## Treatment Options for Patients with Cirrhosis with Ascites

- Cessation of Alcohol use
- Sodium restricted diet (2000mg/day) and education
- Spironolactone 100mg alone may be effective in new ascites
- Dual diuretics: Spironolactone and Furosemide, orally with single daily dosing
- Ratio Spironolactone 100mg: Furosemide 40mg, increase every 3-5 days
- Fluid restriction not necessary unless serum sodium  $\leq 125$  mmol/L
- Maximum doses are Spironolactone 400mg: Furosemide 160mg
- Amiloride or Eplerenone substituted for Spironolactone or tender gynecomastia
- Consider stopping NSAIDs, ACE Inhibitors, Angiotensin Receptor blockers, Propranolol
- Liver transplant evaluation
- Albumin infusion in patients with cirrhosis and ascites remains controversial (ANSWER vs. MACTH study)

Lancet 2018; 391: 2417-2429.

J Hepatology 2018; 69: 1250-1259.

Over the last few months R.S. has been unable to receive diuretics due to hyponatremia. What are other management steps that might be considered for his ascites:

- 1) TIPS
- 2) Large volume paracentesis with albumin repletion
- 3) Liberalize his 2g/day sodium diet to 4g/day
- 4) Urgent liver transplant listing: refractory ascites gives extra listing points
- 5) Increasing non-selective beta-blocker

Over the last few months R.S. has been unable to receive diuretics due to hyponatremia. What are other management steps that might be considered for his ascites:


- 1) TIPS
- 2) Large volume paracentesis with albumin repletion
- 3) Liberalize his 2g/day sodium diet to 4g/day
- 4) Urgent liver transplant listing: refractory ascites gives extra listing points
- 5) Increasing non-selective beta-blocker

## Management of Refractory Ascites

- 10% of patients with cirrhosis with ascites
- Unresponsive to 2g sodium diet and high dose diuretics  
OR
- Clinically significant complications of diuretics (encephalopathy, creatinine > 2g/dL, sodium < 120 mmol/L, potassium > 6 mmol/L)
- Options include serial LVPs vs. TIPS → liver transplant
- In LVP ≥ 5L, albumin infusion of 6-8g/L removed improves survival and prevents post-paracentesis circulatory dysfunction
- Use of nonselective beta blockers in refractory ascites has conflicting data, but should be reduced or discontinued in SBP < 90mmHg, acute kidney injury

Hepatology 2021; 74: 1014-1048.  
Gut 2021; 70: 9-29.

## Transjugular Intrahepatic Portosystemic Shunt



## TIPS for Refractory Ascites

- Survival advantage with TIPS in patients with refractory ascites in several recent meta-analyses
- TIPS causes gradual suppression of neurohormonal vasoconstrictors over 4-6 months
- By 6 months about 80% of patients will clear their ascites
- Careful patient selection: MELD score < 18
- Patients with MELD > 18, hepatic encephalopathy (HE), advanced age (70), cardiopulmonary insufficiency and sarcopenia at greater risk of complications post TIPS
- TIPS stents with smaller diameter (8-10mm) have been equally effective in ascites management, reduce risk of HE

J Gastroenterology Hepatology 2015; 30: 389-395.  
Semin Liver Disease 2018; 38: 87-96.  
Clin Gastroenterology Hepatology 2019; 17: 2793-2799.


RS has admission sodium of 121, creatinine of 2.1, and evidence of spontaneous bacterial peritonitis (SBP) on diagnostic tap (>250 PMNs). In addition to starting Ceftriaxone, your next steps in management should include:

- 1) Stop Nadolol
- 2) Albumin infusion 1.5g/kg IV
- 3) Check urinalysis
- 4) Start Pentoxifylline 300mg TID
- 5) 1,2 and 3

RS has admission sodium of 121, creatinine of 2.1, and evidence of spontaneous bacterial peritonitis (SBP) on diagnostic tap (>250 PMNs). In addition to starting Ceftriaxone, your next steps in management should include:

- 1) Stop Nadolol
- 2) Albumin infusion 1.5g/kg IV
- 3) Check urinalysis
- 4) Start Pentoxifylline 300mg TID
- 5) 1, 2 and 3

## Natural History of Ascites from Cirrhosis




## Hepatorenal Syndrome – clinical features

- Cirrhosis with ascites
- Diagnosis of AKI by International Club of Ascites-Acute Kidney Injury Criteria
- No creatinine improvement after 2 days diuretic withdrawal
- No creatinine improvement after 2 days volume expansion with albumin (1g/kg body weight daily)
- Absence of shock, nephrotoxins
- Bland urine sediment/no signs structural kidney injury

AASLD Practice Guidance. Hepatology 2021; 74: 1014-1041

## Natural History of Hepatorenal Syndrome




\*Type I HRS now called HRS-AKI

Gastroenterology 2002; 122:1658.  
Hepatology 2021; 74: 1014-1041.

## Hepatorenal Syndrome – management

- Treatment of underlying liver disease (alcoholic hepatitis, HBV)
- Prevention with albumin infusion in SBP
- Cessation of nonselective beta blockers in SBP
- Treatment with vasoconstrictor drug in combination with albumin
- Terlipressin + Albumin – Terlipressin just approved in U.S. (9/2022)
- Norepinephrine + Albumin equally effective to Terlipressin, less data
- Albumin/Octreotide/Midodrine
- Renal replacement therapy as bridge to liver recovery or transplant
- Liver transplantation

## Natural History of Ascites from Cirrhosis



## Spontaneous Bacterial Peritonitis: Treatment

Systemic antibiotics for Community Acquired SBP

- Ceftriaxone or Cefotaxime
- Avoid aminoglycosides
- Most patients will respond to 5 day course of treatment

Cessation of nonselective beta blockers

Albumin IV on Day 1 and Day 3 with any of following:

- BUN > 30mg/dL
- Creatinine > 1.0 mg/dL
- Serum bilirubin > 4mg/dL

AASLD Practice Guidance. Hepatology 2021; 74: 1014-1041

## Spontaneous Bacterial Peritonitis: Primary & Secondary Prophylaxis

- Childs B or C patients with cirrhosis hospitalized with GI bleeding (IV Ceftriaxone)
- Ascites total protein <1.5g/dL AND  
Renal failure (Creatinine  $\geq$  1.2, BUN  $\geq$  25 or serum Na  $\leq$ 130) OR  
Liver failure (Child score  $\geq$  9 or Bilirubin  $\geq$  3)
- Prior history of SBP
- Trimethoprim/Sulfa 1DS tablet daily, Ciprofloxacin 500mg daily
- Intermittent/weekly dosing of antibiotics may be inferior to daily dosing

AASLD Practice Guidance. Hepatology 2021; 74: 1014-1041

R.S. is being treated for SBP, but his encephalopathy persists. Lactulose was held on admission due to concern for intravascular volume depletion. Other potential treatment options for encephalopathy include:

- 1) Hemodialysis
- 2) Rifaximin 550mg BID
- 3) 4 Liters Polyethylene Glycol (PEG)
- 4) Neomycin 6g BID
- 5) Protein restriction

R.S. is being treated for SBP, but his encephalopathy persists. Lactulose was held on admission due to concern for intravascular volume depletion. Other potential treatment options for encephalopathy include:

- 1) Hemodialysis
- 2) Rifaximin 550mg BID
- 3) 4 Liters Polyethylene Glycol (PEG)
- 4) Neomycin 6g BID
- 5) Protein restriction

## Treatment of Hepatic Encephalopathy

- Determine precipitant of hepatic encephalopathy and treat
- (Infection, Electrolytes, GI Bleeding, Constipation, Dehydration, Sedatives)
- Lower ammonia level
- Lactulose aiming for 2-4 bowel movements daily → Rifaximin
- Do not restrict protein: Maintain dietary protein intake of 1.2g to 1.5g/kg/day
- Use physical/neurologic exam rather than serial blood ammonia levels once treatment initiated

On day #2, R.S. has massive hematemesis. Urgent endoscopy shows grade III esophageal varices with red wale signs. He has 3 bands placed. Next steps should include all of the following except:

- 1) Octreotide IV for 72 hours
- 2) Consider TIPS before he rebleeds
- 3) Transfuse to keep hemoglobin > 10g/dL
- 4) Continue Ceftriaxone treatment for SBP

On day #2, R.S. has massive hematemesis. Urgent endoscopy shows grade III esophageal varices with red wale signs. He has 3 bands placed. Next steps should include all of the following except:

- 1) Octreotide IV for 72 hours
- 2) Consider TIPS before he rebleeds
- 3) **Transfuse to keep hemoglobin > 10g/dL**
- 4) Continue Ceftriaxone treatment for SBP

## Management of Acute Bleeding in Patients with Cirrhosis


- Management of acute bleeding in patients with cirrhosis depends on location, severity and degree of hemostatic impairment
- For variceal bleeding, major cause is increased portal pressure rather than bleeding diathesis
- For non-variceal bleeding, manage INR, platelet count and fibrinogen level:
  - Vitamin K (usually IV)
  - Transfuse platelet count to >50,000
  - Administer source of fibrinogen to get level  $\geq$  100-120mg/dL (Cryoprecipitate less volume than FFP)
  - Consider antifibrinolytic (Tranexamic or Aminocaproic acid)
- Thrombopoietin (TPO) receptor agonists not effective in acute bleeding

## Management of Acute Variceal Hemorrhage

- Admit to ICU
- Upper endoscopy within 12 hours
- Restrictive blood volume resuscitation  
Initiating PRBC transfusion at hemoglobin of 7 g/dL and maintain hemoglobin at 7-9 g/dL
- Short-term antibiotic prophylaxis (maximum 7 days)  
IV Ceftriaxone 1g/24 hours is the antibiotic of choice
- Octreotide, Somatostatin, Terlipressin for 2-5 days → NSBB
- Consider TIPS in Childs C cirrhosis or Childs B with active bleeding

AASLD Guidelines Hepatology 2017; 65: 310-335.  
Hepatology 2019; 69: 282-293.  
AASLD Guidelines Hepatology 2023.

## Esophageal Varices & Band Ligation




## Early TIPS An Option for Variceal Hemorrhage

- 63 Child B/C patients with cirrhosis with acute variceal bleeding
- All had vasoactive drugs and endoscopic therapy, then randomized:
- 32 underwent TIPS within 72 hours of admission
- 31 continued vasoactive drugs for 3-5 days → Nadolol/Propranolol and continued banding
- 7/31 needed rescue TIPS
- Median follow-up 16 months
- At 1 year, episodes of encephalopathy 18% TIPS vs. 10% pharmacologic (p=.80)
- No significant differences in adverse events


NEJM 2010; 362: 2370-2379.

## Early TIPS An Option for Variceal Hemorrhage

### Rebleeding



### Survival



NEJM 2010; 362: 2370-2379.

If the EGD on R.S. showed isolated bleeding gastric varices, what would your treatment options include:

- 1) Consult vascular radiology for TIPS
- 2) Consult vascular radiology for BRTO
- 3) Cyanoacrylate glue injection
- 4) Continue IV Octreotide and proceed with urgent transplant evaluation
- 5) 1, 2 and 3

If the EGD on R.S. showed isolated bleeding gastric varices, what would your treatment options include:

- 1) Consult vascular radiology for TIPS
- 2) Consult vascular radiology for BRTO
- 3) Cyanoacrylate glue injection
- 4) Continue IV Octreotide and proceed with urgent transplant evaluation
- 5) 1, 2 and 3

## Management of Bleeding Gastric Varices

- Vasoactive drugs, restrictive transfusion, antibiotic prophylaxis
- Banding gastric varices can be technically difficult (IGV1> GOV2> GOV1)
- Cyanoacrylate glue injection
  - Polymerizes into firm clot within varix
  - Risk of distal embolization
  - Not approved by FDA for use in US, center dependent expertise
- TIPS
- Balloon-occluded retrograde obliteration (BRTO)
  - Balloon catheter in draining vessel then instill sclerosant/sponge
  - 90% long-term bleeding control
  - Can increase portal pressure: worsen esophageal varices, ascites
- EUS-guided transesophageal coiling of gastric varices

## Management of Gastroesophageal Varices

- GEV present in 50% patients with cirrhosis: 30-40% compensated, 85% decompensated
- In patients with compensated cirrhosis varices develop at rate of 7-8%/year
- Clinically significant portal hypertension (CSPH) is HVPG  $\geq$  10mmHG
- Presence of clinical decompensation, GEV on endoscopy, portosystemic collaterals or hepatofugal flow on imaging is sufficient to diagnose CSPH
- Elastography + platelet count can be used to diagnose CSPH

Non-invasive staging of chronic liver disease	No cACLD	Possible cACLD	Highly suggestive of cACLD	cACLD	
Liver stiffness (kPa)	<10	10-15	15-20	20-25	>25
Platelet count (K/mm <sup>3</sup> )	NR	NR	If <110 = CSPH	If <150 = CSPH	CSPH**

Risk of decompensation

## Management of Gastroesophageal Varices

- New diagnosis of cirrhosis: EGD to screen for gastroesophageal varices OR ultrasound elastography + platelet count to assess for CSPH
- If varices on EGD OR CSPH by elastography/platelet count, start Carvedilol 6.25mg QD increase to 12.5mg QD if tolerated
- If no varices on original EGD, repeat every 2 years with ongoing liver injury (obesity, alcohol) or 3 years (abstinence, viral elimination) OR repeat elastography + platelet count annually
- EGD at time of clinical decompensation (ascites, encephalopathy) OR assume CSPH and consider Carvedilol
- If cirrhosis but no varices on EGD and no CSPH by elastography → prevent clinical decompensation
- Grade 1 varices → Non-selective beta blocker, Carvedilol preferred and if tolerated no need to repeat EGD
- Grade 2-3 varices → Non-selective beta blocker or variceal ligation

Hepatology 2024; 79: 1180-1211.

## Patient RS

R.S. is slowly recovering from SBP and variceal bleed

Continues IV Ceftriaxone for 5 days → Ciprofloxacin

Creatinine slowly normalizes

Transitions from IV Octreotide → debate about restarting Nadolol

Encephalopathy improves with initiation of Rifaximin and improvement in SBP, hyponatremia

MELD is 19

His wife asks you what else can be done?

## Optimal Timing of Referral for LT

Clinical Decompensation + Biochemical Decompensation (MELD >15)

- Encephalopathy
- Ascites
- Variceal Hemorrhage or chronic GI bleed from portal hypertensive gastropathy
- Hepatocellular Carcinoma
- Hepatorenal syndrome
- Hepatopulmonary syndrome or Portopulmonary Hypertension


Other considerations:

- Acute Liver Failure
- Severe Alcoholic Hepatitis
- Poor quality of life or recurrent, resistant infections in PSC/PLD

## Timing: What is MELD?

- Model for End-stage Liver Disease
- Originally created to predict short term mortality post TIPS
- Basis for liver allocation in U.S. since 2/2002
- MELD-Sodium used since 1/2016
- MELD 3.0 used since 7/2023 (In Epic .MELDPELD)
- 5 objective lab tests (Sodium, Total bilirubin, Creatinine, INR, Albumin + gender)
- Highly predictive of 3-month mortality in patients with cirrhosis
- MELD of 15 is threshold for patient survival with transplantation > survival without transplantation

## Liver Disease Etiology of Adult Transplant Recipients



SRTR.transplant.hrsa.gov 2020

## Exclusions for Liver Transplantation


- MELD Score <15
- Severe cardiac or pulmonary disease
- AIDS
- Ongoing alcohol or illicit substance abuse
- HCC with metastatic spread
- Uncontrolled sepsis
- Anatomic abnormality that precludes liver transplant
- Intrahepatic cholangiocarcinoma
- Extrahepatic malignancy
- Persistent non-compliance
- Lack of adequate social support system

Hepatology 2014; 59: 1144-1165.

## Patient RS

- RS is listed for liver transplantation with MELD of 19
- His family wants to know how long until he gets a deceased donor liver transplant?
- What can he do to increase his chances of receiving a transplant?

Liver Transplants in 2023 in 11 UNOS Regions



## Living Donor Liver Transplantation

- ~6% of liver transplants in U.S. in 2023
- Patient must be listed for deceased donor transplant
- Anticipated prolonged time on wait list with MELD >15
- Recipients of LDLT are less sick: MELD 15-20
- Has family member or acquaintance with close relationship – no coercion
- In adult, take the right lobe (2/3 mass of liver) from donor → recipient
- Pediatric cases use left lobe living donor transplant

## Patient RS

- RS has multiple ER visits for protruberant and painful umbilical hernia, ?hernia incarceration
- MELD remains ~19-20
- General surgery recommends hernia repair
- General surgery requests pre-operative “hepatology clearance”

R.S. has risk of peri-operative mortality at 30 days following elective hernia repair closest to:

- 1) 1%
- 2) 10%
- 3) 30%
- 4) 80%

R.S. has risk of peri-operative mortality at 30 days following elective hernia repair closest to:



- 1) 1%
- 2) 10%
- 3) 30%
- 4) 80%

## Surgical Risk in Patients with Cirrhosis

- Child-Turcotte-Pugh (CTP) and MELD score predict peri-operative morbidity and mortality
- Most CTP studies from cardiac or abdominal surgical literature
- Child's A: 10%, Child's B: 30%, Child's C: 80%
- Mayo clinic study – looked at pre-operative MELD, age and ASA class in 772 patients with cirrhosis undergoing surgery
- MELD was best predictor of 30-day and 90-day mortality
- MELD  $\leq 7$ : 5.7%, MELD 8-11: 10.3%, MELD 12-15: 25.4%
- VOCAL-Penn score (<http://www.vocalpennscore.com>) looks at urgency, type of surgery, age, albumin, platelet count, bilirubin, BMI, ASA class, +/- fatty liver

Gastroenterology 2007; 132: 1261-1269.  
Hepatology 2021; 73: 204-218.

## Pre-operative MELD and Post-operative Mortality



Gastroenterology 2007; 132: 1261-1269.



VOCAL-Penn  
Cirrhosis Surgical Risk Score

Enter the following data: SI Units

Age:

Albumin:

Total Bilirubin:

Platelet Count:

BMI  $\geq 30$ :  No  Yes

MASLD:  No  Yes

ASA Score:  2  3  4

Emergency:  No  Yes

Surgery Type:

Use | Surgery Types | About | VOCAL

**Predicted Postoperative Outcomes:**

30-day mortality:

90-day mortality:

180-day mortality:

90-day decompensation:

VOCAL-Penn predicts post-operative mortality for patients with cirrhosis. It incorporates the type and circumstance of surgery under consideration, and utilizes other important and readily available clinical data. Predictions may be used to risk-stratify patients for surgery and help inform decisions to pursue surgical or non-surgical management.

*"I believe the role of the VOCAL-Penn Cirrhosis Surgical Risk Score is to help surgeons and hepatologists make better decisions for their patients."*

Questions or comments? [Email Us.](#)

[www.vocalpennscore.com](http://www.vocalpennscore.com)

## Summary

- Hepatic decompensation reduces survival
- MELD and CTP scores predict 3-month and 1-year mortality in patients with cirrhosis
- TIPS > LVP in management of refractory ascites
- Prevention of HRS includes antibiotics in UGI bleeding, IV albumin in SBP/LVP
- Nonselective beta blocker cessation in SBP
- Consider early TIPS in Childs B/C variceal bleeds
- Gastric varices: cyanoacrylate glue, TIPS, BRTO, EUS coiling in select patients
- Refer for liver transplantation: MELD  $\geq 15$  + clinical decompensation
- CTP, MELD and VOCAL-Penn score useful in estimating surgical risk in patients with cirrhosis

## Select References

- SW Biggins et al. Diagnosis, Evaluation and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by American Association for the Study of Liver Disease. *Hepatology* 2021; 74: 1014-1041.
- DE Kaplan et al. AASLD Practice Guidance on Risk Stratification and Management of Portal Hypertension and Varices in Cirrhosis. *Hepatology* 2024; 79: 1180-1211.
- AU Mahmud et al. Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis. *Hepatology* 2021; 73: 204-218.
- P Martin et al. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by American Association for the Study of Liver Diseases and American Society of Transplantation. *Hepatology* 2014; 59: 1144-1165.
- H Vilstrup et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guidelines by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology* 2014; 60: 715-735.